CHANGES IN PLASMA MIR-21 EXPRESSION LEVELS IN PATIENTS WITH ADVANCED COLON CANCER BEFORE AND AFTER TREATMENT WITH OXALIPLATIN AND CLINICAL SIGNIFI- CANCE

HUANG HUIBIN¹, YAN GUOHUI^{2, 3, 4}, YAN SHUIDI¹, LEI SHEN⁵, TIAN WEIMIN^{3, 4, 6}, ZHANG YANG^{1, 7, 8,}

¹Center of Clinical Laboratory, Zhongshan Hospital, School of Medicine, Xiamen University, The Hu Bin South Road NO. 201-209, Xia Men, Fu Jian Province, China, 361004 - ²The Department of Ultrasound, Zhongshan Hospital, School of Medicine, Xiamen University, The Hu Bin South Road NO. 201-209, Xia Men, Fu Jian Province, China, 361004 - ³The Medical Department of the Xiamen University, Xia Men, 361000 - ⁴The Medical Department of the Fu Jian Medical University, Fu Zhou, 350000 - ⁵The Institute of Medical Technology and Engineering, The Fu Jian Medical University, the New District of University, the North Road NO.1, Fu Zhou, Fu Jian Province, China, 350000 - ⁶The Department of Paediatrics, Zhongshan Hospital, School of Medicine, Xiamen University, The Hu Bin South Road NO. 201-209, Xia Men, Fu Jian Province, China, 361004 - ⁷The Department of public health, The Xia Men University, XiaMen, 361004 - 8The Department of the Medicine, The Institute of Medical Technology and Engineering, The Fu Jian Medical University, Fu Zhou, 350000

Objective: This work aimed to investigate the changes in plasma microRNA-21 and its clinical significance in patients with advanced colon cancer before and after treatment with tiggio combined with oxaliplatin.

Methods: RT-PCR was used to detect the relationship between plasma microRNA-21 and the therapeutic effect of tiggio combined with oxaliplatin in 73 patients with advanced colon cancer before and after treatment.

Results: The level of miR-21 in the plasma of patients with advanced colon cancer was significantly higher than that of the control group before treatment (t=25.31, P<0.001). Compared with 1 week before treatment, miR-21 significantly decreased in the plasma of patients with advanced colon cancer 2 weeks and 6 weeks after treatment (F=219.48, P<0.001). The level of miR-21 in the CR + PR group was significantly lower than that of the SD + PD group (t=-8.56, P<0.001).

Conclusion: Plasma miR-21 may be the sensitive index for predicting the efficacy of tegafur combined with oxaliplatin in patients with advanced colon cancer, and it may guide the clinical treatment of advanced colon cancer.